Navigation Links
LifeCare Holdings, Inc. Announces Year-end Results
Date:3/28/2008

n in face of our senior subordinated notes for approximately $1.5 million. Partially offsetting the gain was the write-off of capitalized financing cost of $0.1 million recorded in connection with the retirement of these senior subordinated notes.

Excluding the impairment charge and the compensation and benefits accrual for 2007, and the impairment charge, gain on early extinguishment of debt, and the insurance recovery for 2006, expenses increased by $14.9 million from the same period in prior year. Rent expense increased by $3.6 million during the 2007 period in connection with the increases in bed capacity during 2007. Net interest expense increased by $3.1 million during the 2007 period as a result of an increase in the LIBOR rates during 2007 and in the margin spread as the result of the amendments to our senior secured credit facility discussed in the Liquidity and Capital Resources section below. The remaining $8.2 million increase in expenses was primarily attributable to an increase in salaries, wages and benefits of $8.3 million, and an increase in outside services, contract labor and other operating expenses of $3.1 million. These increases resulted from inflation and the increases in bed capacity during 2007. These increases were offset by a decrease in the provision for doubtful accounts of $2.9 million and a decrease in depreciation and amortization expense of $0.6 million. The provision for doubtful accounts during 2006 included an additional provision of $1.7 million for the impact of a conversion to a new patient accounting system during 2006.

Credit Agreement EBITDA

For the year-ended December 31, 2007, Credit Agreement EBITDA, was $47.5 million, including a $6 million cure amount discussed below, a decrease of $10.3 million, or 17.8% from the prior year period. The decrease in Credit Agreement EBITDA, on a dollar and percentage of net patient service revenue basis, was primarily due to the reduction in revenues associated with
'/>"/>

SOURCE LifeCare Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. LifeCare Hospitals of Wisconsin Unveils Center for Advanced Wound Healing
2. LifeCare Holdings, Inc. Announces Third Quarter Results
3. Batesville Holdings, Inc., Appoints Doug Wilson Senior Vice President Human Resources
4. Previously Disclosed Changes in Board Composition of NightHawk Radiology Holdings, Inc. Prompt Notice of Noncompliance from the Nasdaq Global Market
5. Solera Holdings, Inc. Appoints Jason Brady as General Counsel
6. Duane Reade Holdings, Inc. to Report Fourth Quarter and Full Year 2007 Financial Results
7. Whitemark Homes Signs Letter of Intent to Acquire Metiscan Holdings, Inc.
8. Vallon Holdings, LLC Launches New Subsidiary Focused on Contract Resources for the Minneapolis-St. Paul Life Science Industry
9. NightHawk Radiology Holdings, Inc. Announces Board Member Departure
10. NightHawk Radiology Holdings, Inc. to Speak at the Cowen and Company 28th Annual Health Care Conference on March 18, 2008
11. Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... (PRWEB) March 06, 2015 Saving Moses, ... around the world is traveling to Angola, Africa March ... of their malnutrition program. , This will be the ... in Angola, demonstrating their commitment to the region’s population ... The team will engage with the mothers and babies ...
(Date:3/6/2015)... 2015 Ticket Down is a reputable source ... at the Moda Center. After being away from the ... showing no signs of letting up on his “Garth Brooks ... his wife, Trisha Yearwood, to venues around the United States. ... critically acclaimed tour to the Moda Center in Portland, OR. ...
(Date:3/6/2015)... California (PRWEB) March 06, 2015 ... known as the pharmacokinetics of a drug refers to ... pharmaceutical compound inside an organism. When toxicity studies are ... or ADMET or ADME/Tox. Increasing focus on lowering costs ... of ADME-toxicology testing worldwide. The traditional drug development model ...
(Date:3/6/2015)... As the Muscular Dystrophy Association continues ... organization has hired two new Scientific Program Officers, Amanda ... report to Grace Pavlath, Ph.D, who joined MDA late ... Director, and together will lead MDA as it accelerates ... for various types of neuromuscular and motor neuron diseases. ...
(Date:3/6/2015)... “On Tap” takes the audience on a journey ... the silver screen and to modern day rhythm tap. ... their famous eye-high kicks! Producers, directors and choreographers Mary Six ... dancing in this robust show, showcasing one of the only ... , “On Tap” is proud to host guest stars ...
Breaking Medicine News(10 mins):Health News:Saving Moses Returns to Angola to Continue Giving Infants and Children a Chance to Live 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2
... NASHVILLE, Tenn., Nov. 10 Healthcare Realty,Trust Incorporated (NYSE: ... quarter,ended September 30, 2008. Funds from operations ("FFO") per ... same period in 2007. FFO,per diluted common share totaled ... with the prior year,s $1.13. FFO would have been ...
... patients or women who want to delay childbirth , , ... the ability to freeze and transplant ovaries, a development ... therapy. , "We can transplant ovaries without any loss ... normally whether it,s fresh or frozen," said co-researcher Dr. ...
... Omega Protein Corporation,(NYSE: OME ), the nation,s ... products, today reported net income of $3.1 million (17,cents ... to net income of,$7.2 million (42 cents a share) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20030516/OMEGALOGO ), Revenues for the third ...
... Inc. ( www.infotrieve.com ), the global leader in business service solutions ... Content SCM software solution at the biopharma company UCB, headquartered in ... ... EON) November 10, 2008 -- Content SCM is Infotrieve,s revolutionary ...
... Thermage, Inc.,(Nasdaq: THRM ), a leader in ... results for the third quarter ended,September 30, 2008. Reliant ... quarter., Thermage revenue for the third quarter of ... million for the third quarter of 2007. Domestic,revenue decreased ...
... LAKE FOREST, Ill., Nov. 10 Hospira, Inc.,(NYSE: ... medication delivery,company, announced today that Ken Meyers has ... Development. In this,capacity, he will lead the global ... high-performance culture and organizational excellence.,Meyers succeeds Henry Weishaar, ...
Cached Medicine News:Health News:Healthcare Realty Trust Announces Third Quarter Results 2Health News:Healthcare Realty Trust Announces Third Quarter Results 3Health News:Healthcare Realty Trust Announces Third Quarter Results 4Health News:Healthcare Realty Trust Announces Third Quarter Results 5Health News:Healthcare Realty Trust Announces Third Quarter Results 6Health News:Healthcare Realty Trust Announces Third Quarter Results 7Health News:Healthcare Realty Trust Announces Third Quarter Results 8Health News:Healthcare Realty Trust Announces Third Quarter Results 9Health News:Freezing Ovaries Preserves Fertility, Scientists Report 2Health News:Freezing Ovaries Preserves Fertility, Scientists Report 3Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 2Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 3Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 4Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 5Health News: Infotrieve's Revolutionary Content SCM Solution Launched at UCB 2Health News: Infotrieve's Revolutionary Content SCM Solution Launched at UCB 3Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 2Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 3Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 4Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 5Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 6Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 7Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 8Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 9Health News:Hospira Names Ken Meyers to Lead Human Resources 2
(Date:3/6/2015)...  Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that ... ROTH Conference on Wednesday, March 11, 2015, at 10:30 a.m. ... Carlton Laguna Niguel in Dana Point, CA. ... and Chief Executive Officer of Palatin Technologies, will provide an ... About Palatin Technologies, Inc. Palatin Technologies, Inc. ...
(Date:3/6/2015)... , March 6, 2015   Prime Therapeutics ... more than 26 million members, today released the following ... (FDA) approval of the first biosimilar to enter the ... Drug Administration (FDA) approval of Sandoz,s Zarxio® to treat ... patients, is a major milestone in our country,s journey ...
(Date:3/6/2015)... März 2015  Unfors RaySafe, Marktführer für ... dem European Congress of Radiology (ECR) in ... 1.000. Installation seines Systems zur Strahlendosimetrie RaySafe ... http://photos.prnewswire.com/prnh/20150304/179432LOGO Das RaySafe i2 ... Informationen über die Dosis der Röntgenstreustrahlung gibt, ...
Breaking Medicine Technology:Prime Therapeutics welcomes FDA's approval of first biosimilar in U.S., but says more clarity is needed 2Prime Therapeutics welcomes FDA's approval of first biosimilar in U.S., but says more clarity is needed 3Unfors RaySafe, ein Unternehmen von Fluke Biomedical, feiert 1.000. Installation seines Systems zur Echtzeit-Strahlendosimetrie 2Unfors RaySafe, ein Unternehmen von Fluke Biomedical, feiert 1.000. Installation seines Systems zur Echtzeit-Strahlendosimetrie 3
... Presented at the 2008 AACR Annual Meeting, SOMERSET, ... today announced that Dr. Intae Lee with the University ... a,promising radiation sensitizer for lung cancer treatment. Dr. Lee ... a poster at the 2008 American,Association of Cancer Research ...
... April 14, at 8:30 a.m. E.T. at ... http://www.isispharm.com , ... ) announced additional results from its,ongoing Phase 2 open-label extension (OLE) ... exposed to,mipomersen for as long as 16 months, the safety profile ...
Cached Medicine Technology:Alfacell's ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment 2Alfacell's ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment 3Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 2Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 3Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 4Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 5Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 6
20 GA TITANIUM RETINAL FORCEPS...
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
Permits rotation of the globe during examination. Overall length,123mm....
Medicine Products: